Birchler Brian 4

4 · IONIS PHARMACEUTICALS INC · Filed Apr 17, 2026

AI-generated summary of this filing

Updated Apr 17, 2026

Ionis (IONS) EVP Brian Birchler Receives RSUs, Sells Shares

What Happened

Brian Birchler, EVP of Corporate and Development Operations at Ionis Pharmaceuticals, had 1,875 restricted stock units vest on 2026-04-15 (converted to 1,875 shares at $0). He then sold 973 of those shares in an automatic sale on 2026-04-16 for a weighted average price of $75.04, generating approximately $73,016. The Form 4 also reports a derivative conversion/disposition entry for 1,875 shares on 2026-04-15 (reported at $0).

Key Details

Transaction dates: RSU vest/conversion 2026-04-15; open-market sale (tax withholding) 2026-04-16. Filing date: 2026-04-17 (appears timely).
Sale price: weighted average $75.04; reported range $75.01–$75.06 across multiple trades.
Cash proceeds: ~ $73,016 from sale of 973 shares.
Shares owned after transaction: not specified in the provided filing excerpt.
Notable footnotes: (F1) shares acquired via RSU vesting; (F2) sale was automatic to cover required tax withholding under the 2011 Equity Incentive Plan; (F3) weighted-average pricing details and offer to provide per-trade prices on request; (F4/F5) each RSU equals one share and RSUs vest in four equal annual installments and may be paid in shares or cash.

Context

These entries reflect RSU vesting and an automatic sell-to-cover for tax withholding—not an open-market purchase or directional trade by the insider. RSU vesting (derivative conversion) is a non-cash event; the subsequent sale is routine to satisfy tax obligations. If you want the exact per-trade prices within the reported range, the filer offers to provide that detail on request.

Form 4

Period: 2026-04-15

EVP, Corp and Development Ops

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-04-15+1,875→ 68,473 total
Sale
Common Stock
[F2][F3]
2026-04-16$75.04/sh−973$73,016→ 67,500 total
Exercise/Conversion
Restricted Stock Unit
[F4][F5]
2026-04-15−1,875→ 48,926 total
Exercise: $0.00From: 2026-04-15→ Common Stock (1,875 underlying)

Footnotes (5)

[F5]Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
[F1]Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
[F2]The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.01 to $75.06 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
[F4]Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

Signature

By: Patrick R. O'Neil, attorney-in-fact For: Brian Birchler|2026-04-17

1 file